Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12563702.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systemic onset juvenile rheumatoid arthritis (JRA) accounts for 10-15% of all JRA. Macrophage activation syndrome (MAS), which can also be considered as secondary hemophagocytic lymphohistiocytosis, is a potentially life-threatening complication of systemic onset JRA. We describe a child with systemic onset JRA who developed MAS after initiation of etanercept therapy.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Juvenile
- Histiocytosis, Non-Langerhans-Cell
- Immunoglobulin G
- Macrophage Activation